Browsing Tag
CagriSema
3 posts
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.
Novo Nordisk’s CagriSema demonstrates superior weight loss results in REDEFINE 1 trial
Novo Nordisk A/S has unveiled significant findings from its REDEFINE 1 trial, marking a major advancement in the…